651 related articles for article (PubMed ID: 3607784)
41. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW
Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968
[TBL] [Abstract][Full Text] [Related]
42. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
43. Biomodulation of 5-fluorouracil with antifolates.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
[TBL] [Abstract][Full Text] [Related]
44. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
[TBL] [Abstract][Full Text] [Related]
45. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.
Samuels LL; Moccio DM; Sirotnak FM
Cancer Res; 1985 Apr; 45(4):1488-95. PubMed ID: 3978616
[TBL] [Abstract][Full Text] [Related]
46. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
47. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
[TBL] [Abstract][Full Text] [Related]
48. [Sequential methotrexate and 5-fluorouracil].
Sasaki T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1907-10. PubMed ID: 8978795
[TBL] [Abstract][Full Text] [Related]
49. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
50. [Improving the anti-tumor activity of 5-fluorouracil by methotrexate].
Konishi T; Noie T; Abe T; Agawa S; Furushima K; Ito K; Mafune K; Makuuchi M; Teruya M; Nouchi T
Gan To Kagaku Ryoho; 1999 Mar; 26(4):431-9. PubMed ID: 10097739
[TBL] [Abstract][Full Text] [Related]
51. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
52. The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth.
Fisher B; Rubin H; Saffer E; Wolmark N
Cancer Res; 1976 Aug; 36(8):2714-9. PubMed ID: 1277181
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
54. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
[TBL] [Abstract][Full Text] [Related]
55. [Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
Maruyama M; Takamatsu S; Sugano N; Ebuchi M; Endo M; Yuasa Y
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2131-6. PubMed ID: 9388524
[TBL] [Abstract][Full Text] [Related]
56. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
57. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer.
Ikeda M; Okada S; Ueno H; Okusaka T; Tanaka N; Kuriyama H; Yoshimori M
Hepatogastroenterology; 2000; 47(33):862-5. PubMed ID: 10919048
[TBL] [Abstract][Full Text] [Related]
59. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model.
Dionet CA; Rapp M; Tchirkov A
Anticancer Res; 2002; 22(2A):721-5. PubMed ID: 12014642
[TBL] [Abstract][Full Text] [Related]
60. [Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
Xing FY; Liu WH; Dong W; Zhang SL; Gu BW; Okazaki K; Naito H; Inoue T; Wu JT; Tamura S
Gan To Kagaku Ryoho; 1993 Feb; 20(2):259-63. PubMed ID: 8434964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
